Vivos Therapeutics, Inc. (NASDAQ: VVOS) reported Q3 EPS of ($1.75), $0.88 better than the analyst estimate of ($2.63). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $4.69 million.

For earnings history and earnings-related data on Vivos Therapeutics, Inc. (VVOS) click here.